Apr 17, 2020
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma | US & EU Market Sizes from 2017 to 2030, Details of Marketed & Emerging Therapies Kymriah (Novartis) & KTE-X19 (Gilead Sciences)
Jan 28, 2020
2019 CAR-T Cell Therapy Market Study: Current Status, Patent Landscape, Funding, Deals, Research, Applications, Technologies, Marketed Products, Ongoing & Late Stage Clinical Trials
Oct 03, 2018
Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types of B-Cell Lymphoma
Jul 30, 2018
Current Research & Developments Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy
Dec 10, 2017
New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma Patients
Dec 08, 2017
Seattle Cancer Care Alliance Selected as Authorized Treatment Center for Yescarta(TM) - A Novel, New Immunotherapy Treatment
Dec 04, 2017
Moffitt Cancer Center Treats First U.S. Patient with Newly FDA-Approved CAR-T Therapy
Oct 19, 2017
BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta(TM) (Axicabtagene Ciloleucel) CAR T-Cell Therapy
Oct 18, 2017
FDA Approves Second LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment
Oct 18, 2017
FDA Approves Yescarta(TM), Revolutionary CAR-T Immunotherapy for Non-Hodgkin's Lymphoma Patients
Oct 18, 2017
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
Sep 05, 2017
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma's CAR-T Therapy Axicabtagene Ciloleucel
Jun 24, 2017
European Hematology Association: Clinical and Biologic Covariates of Outcomes in ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive non-Hodgkin Lymphoma (NHL)